Topotarget jumps on lymphoma data for belinostat
Topotarget A/S (CSE:TOPO) jumped DKK1.52 (135%) to DKK2.65 on Friday after reporting that once-daily IV belinostat met the primary endpoint of an objective response rate of 20% or greater in the pivotal Phase II BELIEF (PXD101-CLN-19) trial to treat peripheral T cell lymphoma (PTCL). Topotarget said the data are being further analyzed and will be reported next quarter. The open-label, international trial enrolled 129 patients with relapsed or refractory PTCL who failed one or more systemic therapy. Belinostat is a small molecule histone deacetylase (HDAC) inhibitor.
Topotarget said partner Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) plans to submit an NDA to FDA for belinostat next half. Spectrum, which has rights from Topotarget to co-develop and commercialize belinostat in North American and India, gained $0.22 to $12.51 on Friday. ...